Security Snapshot

GILEAD SCIENCES, INC. - Common Stock (GILD) Institutional Ownership

CUSIP: 375558103

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

2,183

Shares (Excl. Options)

1,089,824,876

Price

$122.74

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
GILD on Nasdaq
Shares outstanding
1,236,593,901
Price per share
$139.37
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
1,089,824,876
Total reported value
$133,618,662,312
% of total 13F portfolios
0.05%
Share change
+28,266,901
Value change
+$3,512,494,509
Number of holders
2,183
Price from insider filings
$139.37
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • GILD - GILEAD SCIENCES, INC. - Common Stock is tracked under CUSIP 375558103.
  • 2183 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 2,183 to 271 between Q4 2025 and Q1 2026.
  • Reported value moved from $133,618,662,312 to $993,751,304.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 2183 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 375558103?
CUSIP 375558103 identifies GILD - GILEAD SCIENCES, INC. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of GILEAD SCIENCES, INC. - Common Stock (GILD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.2% $10,799,623,829 101,739,273 BlackRock, Inc. 31 Mar 2025
FMR LLC 5.3% $8,044,315,376 65,539,477 FMR LLC 31 Dec 2025
Capital World Investors 4.3% $5,714,571,769 53,834,873 Capital World Investors 31 Mar 2025

As of 31 Dec 2025, 2,183 institutional investors reported holding 1,089,824,876 shares of GILEAD SCIENCES, INC. - Common Stock (GILD). This represents 88% of the company’s total 1,236,593,901 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of GILEAD SCIENCES, INC. - Common Stock (GILD) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 10% 123,195,578 +5.9% 0.26% $15,121,025,249
VANGUARD GROUP INC 9.8% 121,097,336 +1.8% 0.22% $14,863,487,020
FMR LLC 5.3% 65,579,490 +8.7% 0.41% $8,049,226,574
STATE STREET CORP 4.9% 60,240,518 +1.9% 0.25% $7,393,921,179
Capital World Investors 3.5% 42,872,129 -5.1% 0.72% $5,262,268,432
GEODE CAPITAL MANAGEMENT, LLC 2.4% 29,696,002 -0.78% 0.22% $3,637,368,762
PRICE T ROWE ASSOCIATES INC /MD/ 2.2% 27,698,660 +4.5% 0.37% $3,399,734,000
Dodge & Cox 2.1% 26,283,511 -13% 1.7% $3,226,038,140
Capital Research Global Investors 2% 25,307,071 -16% 0.57% $3,106,193,871
MORGAN STANLEY 1.9% 23,512,734 -0.94% 0.17% $2,885,953,592
BANK OF AMERICA CORP /DE/ 1.9% 23,121,620 +15% 0.21% $2,837,947,589
JPMORGAN CHASE & CO 1.9% 23,035,763 +8.8% 0.19% $2,827,409,785
NORGES BANK 1.7% 21,322,732 0.28% $2,617,152,126
WELLINGTON MANAGEMENT GROUP LLP 1.3% 15,907,304 -38% 0.34% $1,952,462,494
Invesco Ltd. 1.3% 15,584,341 +2.9% 0.29% $1,912,822,026
Bank of New York Mellon Corp 1.2% 15,215,384 +6.8% 0.33% $1,867,536,232
NORTHERN TRUST CORP 1.1% 14,057,956 -1.8% 0.22% $1,725,473,519
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 1.1% 13,000,814 +0.09% 0.34% $1,595,719,911
Legal & General Group Plc 0.83% 10,317,613 +1% 0.28% $1,266,383,821
Amundi 0.77% 9,520,135 +26% 0.36% $1,168,501,370
BARCLAYS PLC 0.74% 9,115,483 +76% 0.45% $1,118,834,386
DIMENSIONAL FUND ADVISORS LP 0.72% 8,846,313 -7.4% 0.23% $1,085,839,581
GOLDMAN SACHS GROUP INC 0.71% 8,752,513 +23% 0.15% $1,074,283,499
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.65% 8,006,790 +0.96% 0.15% $982,753,405
AMERIPRISE FINANCIAL INC 0.63% 7,800,418 +9.1% 0.22% $957,455,907

Institutional Holders of GILEAD SCIENCES, INC. - Common Stock (GILD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 7,220,718 $993,751,304 -$78,425,570 $139.37 271
2025 Q4 1,089,824,876 $133,618,662,312 +$3,512,494,509 $122.74 2,183
2025 Q3 1,055,277,570 $117,154,382,055 -$2,197,543,603 $111.00 2,009
2025 Q2 1,073,254,023 $118,963,159,666 +$3,514,130,825 $110.87 2,000
2025 Q1 1,043,338,274 $116,881,227,875 -$1,852,497,281 $112.05 1,991
2024 Q4 1,061,928,121 $98,045,307,663 +$1,597,585,192 $92.37 1,868
2024 Q3 1,041,031,806 $87,292,159,028 +$497,071,935 $83.84 1,702
2024 Q2 1,032,141,981 $70,791,566,038 -$264,255,142 $68.61 1,666
2024 Q1 1,039,326,218 $76,098,429,205 -$499,202,917 $73.25 1,705
2023 Q4 1,044,478,354 $84,656,377,441 +$255,439,953 $81.01 1,763
2023 Q3 1,039,821,240 $77,974,757,522 -$75,610,588 $74.94 1,671
2023 Q2 1,042,887,174 $80,416,194,253 +$427,085,098 $77.07 1,687
2023 Q1 1,034,794,880 $85,819,040,826 +$628,903,617 $82.97 1,717
2022 Q4 1,031,461,660 $88,551,084,722 +$2,216,871,534 $85.85 1,747
2022 Q3 1,003,983,340 $61,982,373,182 +$689,958,176 $61.69 1,570
2022 Q2 993,379,548 $61,392,230,451 +$324,575,776 $61.81 1,587
2022 Q1 988,770,035 $58,777,059,567 -$957,879,872 $59.45 1,567
2021 Q4 1,009,356,244 $73,295,492,986 +$193,423,902 $72.61 1,663
2021 Q3 999,239,167 $69,763,198,043 +$691,955,339 $69.85 1,544
2021 Q2 989,284,689 $68,064,289,407 +$647,772,893 $68.86 1,524
2021 Q1 981,962,949 $63,398,921,279 +$771,179,759 $64.63 1,551
2020 Q4 971,052,591 $56,534,223,402 -$194,225,396 $58.26 1,543
2020 Q3 975,382,123 $61,581,778,990 -$1,221,202,886 $63.19 1,524
2020 Q2 990,066,372 $76,108,860,118 -$470,860,186 $76.94 1,618
2020 Q1 998,079,792 $74,600,178,391 -$1,145,482,309 $74.76 1,633
2019 Q4 1,013,882,391 $65,874,525,082 +$31,658,674 $64.98 1,547
2019 Q3 1,013,158,831 $64,205,170,698 -$201,708,522 $63.38 1,452
2019 Q2 1,017,131,311 $68,703,708,929 +$1,159,368,401 $67.56 1,472
2019 Q1 1,015,569,209 $66,012,744,686 -$243,978,731 $65.01 1,476
2018 Q4 1,019,661,172 $63,734,090,725 +$29,422,887 $62.55 1,478
2018 Q3 1,022,396,822 $78,869,235,633 +$2,219,917,371 $77.21 1,520
2018 Q2 992,982,498 $70,297,342,536 -$2,364,209,399 $70.84 1,516
2018 Q1 1,024,922,600 $77,180,332,612 +$357,307,777 $75.39 1,558
2017 Q4 1,022,247,620 $73,179,775,286 +$1,023,841,433 $71.64 1,574
2017 Q3 1,004,542,606 $81,371,526,834 +$2,310,126,305 $81.02 1,501
2017 Q2 978,374,690 $69,232,836,215 +$313,533,710 $70.78 1,514
2017 Q1 975,372,838 $66,220,816,545 +$5,353,818,575 $67.92 1,515
2016 Q4 991,376,626 $70,992,715,949 -$496,869,443 $71.61 1,565
2016 Q3 994,641,139 $78,638,414,793 -$3,545,904,859 $79.12 1,547
2016 Q2 1,039,317,614 $86,682,066,843 -$2,513,064,923 $83.42 1,587
2016 Q1 1,068,034,773 $98,100,074,299 -$6,517,835,276 $91.86 1,617
2015 Q4 1,137,355,202 $115,088,592,819 -$3,128,093,783 $101.19 1,621
2015 Q3 1,164,695,259 $114,359,980,167 -$3,451,464,869 $98.19 1,561
2015 Q2 1,199,337,377 $140,402,300,771 -$4,005,236,404 $117.08 1,549
2015 Q1 1,234,393,342 $121,177,956,582 -$2,154,329,861 $98.13 1,481
2014 Q4 1,258,378,649 $118,685,414,349 -$4,388,207,356 $94.26 1,426
2014 Q3 1,293,869,876 $137,734,928,602 -$9,497,208,855 $106.45 1,315
2014 Q2 1,377,947,628 $114,268,245,236 -$1,971,113,663 $82.91 1,253
2014 Q1 1,405,078,310 $99,582,400,406 -$880,737,639 $70.86 1,177

Sponsored